We have created a technology platform that allows physicians the opportunity to integrate autologous PRP (Platelet-rich Plasma) and BMCC (Bone Marrow Cell Concentrate) biologic preparations into their practice.
Learn More
The use of a patient’s own biologic preparation complements the natural healing process present in patients but is dependent on a variety of components.
Learn More
Numerous reports on potential applications for PRP and BMCC suggest that autologous PRP and BMCC preparations are considered to support a patient’s natural healing processes.
Learn More
Founder and Chief Executive Officer
Greyledge operations are currently being led by company Founder and CEO – David Karli. He is responsible for all aspects of company development, including the integration of a strong team of professionals to support Greyledge’s innovative approach to regenerative medicine.
President
Zoe Bedford Karli, our President and a Director, officially joined the Greyledge executive team in 2019.
VP of Operations
Mark establishes and leads many of our logistics, quality, and supporting processes as Greyledge Technologies expands its’ services throughout the United States.
Director
Howard Ash is an accomplished Executive with extensive experience in business and finance, who served as CEO, COO, and CFO to a variety of high-profile, international companies.
Director
Mr. Mansour has been actively involved with disruptive technology as an inventor, manager, executive, and coach for more than 3 decades. He has extensive experience within many sectors – Bio-Technology, Consumer Electronics, Computer Science, Energy, Health Sciences, Hospitality, and Publishing. He has spoken often throughout his career on the future of technology and the effects of its disruption.
